TY - JOUR
T1 - The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer
AU - Yamaguchi, Kyoko
AU - Kusaba, Hitoshi
AU - Makiyama, Akitaka
AU - Mitsugi, Kenji
AU - Uchino, Keita
AU - Tamura, Shingo
AU - Shibata, Yoshihiro
AU - Esaki, Taito
AU - Ito, Mamoru
AU - Takayoshi, Kotoe
AU - Tsuchihashi, Kenji
AU - Arita, Shuji
AU - Ariyama, Hiroshi
AU - Akashi, Koichi
AU - Baba, Eishi
N1 - Funding Information:
Conflict of interest Koichi Akashi and Eishi Baba have received research grants from Yakult Honsha, Eli Lilly, Taiho Pharm, Chugai Pharm, and Nippon Kayaku. Taito Esaki received research grants from mentioned above other than Chugai Pharm. Koichi Akashi has received a speaker honorarium from Chugai Pharm. Eishi Baba has received a speaker honorarium from Chugai Pharm and Eli Lilly. Aki-taka Makiyama and Taito Esaki received a speaker honorarium from Yakult Honsha, Eli Lilly, Taiho Pharm, Chugai Pharm, and Nippon Kayaku.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Purpose: Peripheral sensory neuropathy (PSN) and thrombocytopenia are the main dose-limiting toxicities of oxaliplatin for the treatment of advanced gastric cancer (AGC). Because the risk factors for those toxicities in practice have not been clarified, we conducted this prospective study. Methods: AGC patients who received oxaliplatin-based therapy at any of seven institutions participating in the Kyushu Medical Oncology Group were assessed after we obtained written informed consent. Results: A total of 60 patients including 39 males and 21 females were examined. The median age was 66 years. The numbers of patients receiving oxaliplatin as the first, second, or third and later lines of therapy were 39, 16, and 5, respectively. An initial dose of 130, 100, or < 100 mg/m2 oxaliplatin was administered to 12, 39, and 9 patients, respectively. S-1 or capecitabine as a concomitant drug was administered in 54 and 6 patients, respectively. In multivariate analysis, the comorbidity of diabetes mellitus was associated with ≥ grade 2 thrombocytopenia (p = 0.035). No significant risk factor was associated with ≥ grade 2 PSN. However, the accumulated dose of oxaliplatin exhibited a strong correlation with ≥ grade 2 PSN (p = 0.0043), and the predicted accumulated dose of oxaliplatin in which 10% of patients developed ≥ grade 2 PSN was 800 mg/m2. The frequency of PSN in subsequent paclitaxel therapy in patients with ≥ grade 2 or worse PSN in oxaliplatin-based chemotherapy did not increase compared to those with none or grade 1 PSN in oxaliplatin. Conclusion: Thrombocytopenia in AGC patients with diabetes mellitus should be carefully monitored during oxaliplatin-based therapy.
AB - Purpose: Peripheral sensory neuropathy (PSN) and thrombocytopenia are the main dose-limiting toxicities of oxaliplatin for the treatment of advanced gastric cancer (AGC). Because the risk factors for those toxicities in practice have not been clarified, we conducted this prospective study. Methods: AGC patients who received oxaliplatin-based therapy at any of seven institutions participating in the Kyushu Medical Oncology Group were assessed after we obtained written informed consent. Results: A total of 60 patients including 39 males and 21 females were examined. The median age was 66 years. The numbers of patients receiving oxaliplatin as the first, second, or third and later lines of therapy were 39, 16, and 5, respectively. An initial dose of 130, 100, or < 100 mg/m2 oxaliplatin was administered to 12, 39, and 9 patients, respectively. S-1 or capecitabine as a concomitant drug was administered in 54 and 6 patients, respectively. In multivariate analysis, the comorbidity of diabetes mellitus was associated with ≥ grade 2 thrombocytopenia (p = 0.035). No significant risk factor was associated with ≥ grade 2 PSN. However, the accumulated dose of oxaliplatin exhibited a strong correlation with ≥ grade 2 PSN (p = 0.0043), and the predicted accumulated dose of oxaliplatin in which 10% of patients developed ≥ grade 2 PSN was 800 mg/m2. The frequency of PSN in subsequent paclitaxel therapy in patients with ≥ grade 2 or worse PSN in oxaliplatin-based chemotherapy did not increase compared to those with none or grade 1 PSN in oxaliplatin. Conclusion: Thrombocytopenia in AGC patients with diabetes mellitus should be carefully monitored during oxaliplatin-based therapy.
UR - http://www.scopus.com/inward/record.url?scp=85050604113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050604113&partnerID=8YFLogxK
U2 - 10.1007/s00280-018-3652-2
DO - 10.1007/s00280-018-3652-2
M3 - Article
C2 - 30043209
AN - SCOPUS:85050604113
VL - 82
SP - 625
EP - 633
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 4
ER -